Generation Bio reports Q2 EPS (47c), consensus (50c)

Cash, cash equivalents, and marketable securities were $314.1 million as of June 30 , compared to $279.1 million in cash, cash equivalents, and marketable securities as of December 31, 2022. The company continues to believe that its cash position will fund its operating plan into 2025.”We continue to make encouraging progress in the development of our cell-targeted lipid nanoparticle (ctLNP) technology, which is a unique, highly specific, non-viral genetic medicine delivery system for nucleic acid cargoes targeted to the liver as well as non-liver tissues,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “For the remainder of the year, we are focused on demonstrating Factor VIII expression in non-human primates for our hemophilia A program as well as continued development of in-vivo targeting to immune cells with our stealth ctLNPs. These achievements are important for demonstrating our platform’s potential to enable a deep pipeline of hepatic programs and broad portfolios of extrahepatic programs.”